Lipocine (LPCN) announced that enrollment and participant dosing have been completed in its Phase 3 clinical trial evaluating LPCN 1154 for the treatment of postpartum depression. “We look forward to reporting topline safety and efficacy results early in the second quarter of 2026.” said Mahesh Patel, CEO of Lipocine.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LPCN: